CAPR stock forecast, quote, news & analysis

Key Takeaways

• CAPR shares have fallen roughly 27% over the past 30 days, from about $9.06 to near $6.61, extending a broader downtrend ahead of a binary FDA decision.
• The decline follows a July 2026 FDA advisory committee vote of 9–3 against the efficacy of deramiocel for Duchenne muscular dystrophy (DMD) cardiomyopathy.
• The FDA extended the PDUFA target action date to November 22, 2026, after Capricor pivoted to a refined indication focused on upper-limb function.
• Ongoing litigation with NS Pharma over its U.S. distribution agreement, plus a securities class action, adds to the uncertainty.
• Capricor remains pre-revenue, holding approximately $237.9 million in cash as of June 30, 2026, enough to fund operations for at least twelve months.

Capricor Therapeutics (CAPR) Company Overview and Market Position

Capricor Therapeutics is a San Diego-based clinical-stage biotechnology company developing cell- and exosome-based therapies for rare diseases. Its lead product candidate, deramiocel (CAP-1002), is an allogeneic cardiosphere-derived cell (CDC) therapy in late-stage development for Duchenne muscular dystrophy, including DMD-associated cardiomyopathy. Deramiocel has received Orphan Drug, Regenerative Medicine Advanced Therapy (RMAT), and Rare Pediatric Disease designations from the U.S. FDA, along with Orphan Drug and Advanced Therapy Medicinal Product designations in Europe. The company is also advancing its proprietary StealthX exosome platform for targeted therapeutic delivery. Investors follow CAPR primarily because its near-term value is tied to a binary regulatory outcome for deramiocel.

Capricor Therapeutics (CAPR) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, CAPR has declined approximately 27%, moving from a close of $9.06 in mid-September to roughly $6.61. The move has been broadly one-directional, with a brief rebound in late September giving way to renewed selling pressure through October.

The last quarter has been far more volatile. Shares traded near $19–$20 in mid-July before collapsing roughly 64% on July 27, 2026, when the FDA released briefing documents ahead of its advisory committee meeting. A further slide followed the July 29 vote, and although the stock staged a partial recovery into late August, it has since given back much of that ground. Over the trailing three-month period, CAPR is down approximately two-thirds from its mid-July levels.

What Drove CAPR Stock Price in the Last 30 Days

The 30-day decline reflects continued de-risking ahead of a pivotal regulatory decision rather than a single new catalyst. Investors are digesting the fallout from the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee, which in a non-binding 9–3 vote concluded that available evidence did not support deramiocel's efficacy for DMD cardiomyopathy. The agency's briefing documents had raised concerns about changes to the trial's statistical analysis plan and questioned the benefit-risk profile.

On August 24, 2026, the FDA extended the PDUFA target action date to November 22, 2026, after Capricor submitted 24-month open-label extension data from its Phase 3 HOPE-3 trial in support of a refined indication focused on upper-limb function. The regulatory overhang, combined with a securities class action filed in late August and uncertainty surrounding Capricor's lawsuit seeking to rescind its U.S. distribution agreement with NS Pharma, has kept sentiment subdued. With the company generating no product revenue, the shares have drifted lower as the next catalyst approaches.

What Drove CAPR Stock Performance Over the Last Quarter

The quarter's defining event was the July 2026 advisory committee process. Before the market opened on July 27, 2026, the FDA published briefing documents that disputed aspects of Capricor's statistical analysis and effectiveness claims, sending the stock down 64% in a single session. The advisory committee then voted 9–3 against the cardiomyopathy indication, and shares fell further.

Capricor has since sought to reposition deramiocel around upper-limb function, the primary endpoint of the HOPE-3 trial, which the company reported was met with a statistically significant benefit. This strategic pivot led the FDA to accept a major amendment and push the PDUFA date back three months. Broader investor concerns about the NS Pharma distribution dispute and the pending securities litigation have compounded the regulatory uncertainty, keeping the stock under pressure through the quarter.

Trending AI Robots

For investors seeking a data-driven approach to market analysis, Tickeron's Trending AI Robots page curates a selection of AI-powered trading bots. Tickeron offers hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots are featured in this section. These bots vary widely in strategy, timeframe, and performance metrics, allowing users to explore approaches ranging from short-term technical signals to longer-horizon trend models. The curated list is designed to help traders identify tools aligned with their own objectives, and reviewing the page can offer a useful starting point for those interested in automated, algorithm-driven market insights.

CAPR Stock Forecast Drivers: What Investors Should Watch Next

The most important near-term catalyst is the FDA's decision on deramiocel, now targeted for November 22, 2026. The outcome of labeling discussions and the refined upper-limb indication will be central to how the stock trades. Investors should also monitor the resolution of Capricor's litigation with NS Pharma, which could determine how deramiocel is commercialized if approved, and any developments in the securities class action. Financially, the company's cash position of roughly $237.9 million and its stated twelve-month runway provide a buffer, but future financing plans and quarterly results remain worth watching. A potential Priority Review Voucher, if approval is secured, could also represent a meaningful non-dilutive source of capital. As with any pre-revenue biotech, the shares remain highly sensitive to regulatory and clinical outcomes.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations